Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Chronic Low-Grade Inflammation in Metabolic Disorders: Relevance for Behavioral Symptoms

Lasselin J. · Capuron L.

Author affiliations

Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, National Institute of Agricultural Research (INRA) and Bordeaux University, Bordeaux, France

Related Articles for ""

Neuroimmunomodulation 2014;21:95-101

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: February 14, 2014
Issue release date: February 2014

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 1

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Abstract

The ability of cytokines to influence cerebral functions and to induce the development of behavioral alterations is well established in conditions of acute or chronic high-grade activation of the innate immune system. Recent evidence suggests that the release of these immune mediators during chronic low-grade endogenous inflammatory processes may also contribute to the development of behavioral alterations. Metabolic disorders, including obesity, type 2 diabetes and the metabolic syndrome, represent examples of those conditions which are both characterized by a chronic low-grade inflammatory state and an increased prevalence of behavioral disorders. In metabolic disorders, the increased production of acute-phase proteins and cytokines (e.g. C-reactive protein, interleukin-6 and tumor necrosis factor-α), but at relatively low levels, may promote and contribute to the development of behavioral symptoms, including depressive symptoms, cognitive impairment, fatigue, sleep problems and pain. This hypothesis is supported by a growing literature referring both to experimental and clinical findings that will be reviewed here.

© 2014 S. Karger AG, Basel


References

  1. Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:7-24.
  2. Capuron L, Miller AH: Cytokines and psychopathology: lessons from interferon-α. Biol Psychiatry 2004;56:819-824.
  3. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
  4. Park HS, Park JY, Yu R: Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 2005;69:29-35.
  5. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-355.
  6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
  7. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-184.
  8. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N: T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1304-1310.
  9. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R: CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914-920.
  10. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481.
  11. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, Aissat A, Guerre-Millo M, Clement K: Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 2009;94:4619-4623.
  12. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C, Rizkalla S, Clement K: Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010;59:3049-3057.
  13. Rao SR: Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res 2012;61:789-807.
  14. Tapia-Gonzalez S, Garcia-Segura LM, Tena-Sempere M, Frago LM, Castellano JM, Fuente-Martin E, Garcia-Caceres C, Argente J, Chowen JA: Activation of microglia in specific hypothalamic nuclei and the cerebellum of adult rats exposed to neonatal overnutrition. J Neuroendocrinol 2011;23:365-370.
  15. Buckman LB, Thompson MM, Moreno HN, Ellacott KL: Regional astrogliosis in the mouse hypothalamus in response to obesity. J Comp Neurol 2013;521:1322-1333.
  16. Buckman LB, Hasty AH, Flaherty DK, Buckman CT, Thompson MM, Matlock BK, Weller K, Ellacott KL: Obesity induced by a high-fat diet is associated with increased immune cell entry into the central nervous system. Brain Behav Immun 2014;35:33-42.
  17. Lin HY, Huang CK, Tai CM, Kao YH, Tsai CC, Hsuan CF, Lee SL, Chi SC, Yen YC: Psychiatric disorders of patients seeking obesity treatment. BMC Psychiatry 2013;13:1.
  18. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K: The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23:1165-1173.
  19. Evans DL, Charney DS, Lewis L, et al: Mood disorders in the medically ill: scintific review and recommendations. Biol Psychiatry 2005;58:175-189.
  20. Everson-Rose SA, Lewis TT, Karavolos K, Dugan SA, Wesley D, Powell LH: Depressive symptoms and increased visceral fat in middle-aged women. Psychosom Med 2009;71:410-416.
  21. Labad J, Price JF, Strachan MW, Fowkes FG, Ding J, Deary IJ, Lee AJ, Frier BM, Seckl JR, Walker BR, Reynolds RM: Symptoms of depression but not anxiety are associated with central obesity and cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetologia 2010;53:467-471.
  22. Dixon JB, Dixon ME, O'Brien PE: Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003;163:2058-2065.
  23. Gunstad J, Lhotsky A, Wendell CR, Ferrucci L, Zonderman AB: Longitudinal examination of obesity and cognitive function: results from the Baltimore Longitudinal Study of Aging. Neuroepidemiology 2010;34:222-229.
  24. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB: Lower cognitive function in the presence of obesity and hypertension: the Framingham Heart Study. Int J Obes Relat Metab Disord 2003;27:260-268.
  25. Alosco ML, Spitznagel MB, Strain G, Devlin M, Cohen R, Paul R, Crosby RD, Mitchell JE, Gunstad J: Improved memory function two years after bariatric surgery. Obesity (Silver Spring) 2013, E-pub ahead of print, doi: 10.1002/oby.20494.
  26. Shimada H, Miki T, Tamura A, Ataka S, Emoto M, Nishizawa Y: Neuropsychological status of elderly patients with diabetes mellitus. Diabetes Res Clin Pract 2010;87:224-227.
  27. Drivsholm T, de Fine Olivarius N, Nielsen AB, Siersma V: Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 2005;48:210-214.
  28. Impellizzeri FM, Agosti F, De Col A, Sartorio A: Psychometric properties of the fatigue severity scale in obese patients. Health Qual Life Outcomes 2013;11:32.
  29. Anandacoomarasamy A, Caterson ID, Leibman S, Smith GS, Sambrook PN, Fransen M, March LM: Influence of BMI on health-related quality of life: comparison between an obese adult cohort and age-matched population norms. Obesity (Silver Spring) 2009;17:2114-2118.
  30. Lasselin J, Laye S, Barreau JB, Rivet A, Dulucq MJ, Gin H, Capuron L: Fatigue and cognitive symptoms in patients with diabetes: relationship with disease phenotype and insulin treatment. Psychoneuroendocrinology 2012;37:1468-1478.
  31. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ: The association between self-reported sleep quality and metabolic syndrome. PLoS One 2013;8:e54304.
  32. Wachholtz A, Binks M, Suzuki A, Eisenson H: Sleep disturbance and pain in an obese residential treatment-seeking population. Clin J Pain 2009;25:584-589.
  33. Bair MJ, Brizendine EJ, Ackermann RT, Shen C, Kroenke K, Marrero DG: Prevalence of pain and association with quality of life, depression and glycaemic control in patients with diabetes. Diabet Med 2010;27:578-584.
  34. Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, Maisano C, Jones L, Murrah NV, Vaccarino V: Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 2008;64:896-900.
  35. Ladwig KH, Marten-Mittag B, Lowel H, Doring A, Koenig W: Influence of depressive mood on the association of CRP and obesity in 3,205 middle aged healthy men. Brain Behav Immun 2003;17:268-275.
  36. Dixon JB, Hayden MJ, Lambert GW, Dawood T, Anderson ML, Dixon ME, O'Brien PE: Raised CRP levels in obese patients: symptoms of depression have an independent positive association. Obesity (Silver Spring) 2008;16:2010-2015.
  37. Daly M: The relationship of C-reactive protein to obesity-related depressive symptoms: a longitudinal study. Obesity (Silver Spring) 2013;21:248-250.
  38. Capuron L, Poitou C, Machaux-Tholliez D, Frochot V, Bouillot JL, Basdevant A, Laye S, Clement K: Relationship between adiposity, emotional status and eating behaviour in obese women: role of inflammation. Psychol Med 2011;41:1517-1528.
  39. Emery CF, Fondow MD, Schneider CM, Christofi FL, Hunt C, Busby AK, Needleman BJ, Melvin WS, Elsayed-Awad HM: Gastric bypass surgery is associated with reduced inflammation and less depression: a preliminary investigation. Obes Surg 2007;17:759-763.
  40. Alvarez A, Faccioli J, Guinzbourg M, Castex MM, Bayon C, Masson W, Bluro I, Kozak A, Sorroche P, Capurro L, Grosembacher L, Proietti A, Finkelsztein C, Costa L, Day PF, Cagide A, Litwak LE, Golden SH: Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder. BMC Res Notes 2013;6:61.
  41. Chirinos DA, Goldberg R, Gellman M, Mendez AJ, Gutt M, McCalla JR, Llabre MM, Schneiderman N: Leptin and its association with somatic depressive symptoms in patients with the metabolic syndrome. Ann Behav Med 2013;46:31-39.
  42. Sharma S, Fulton S: Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry. Int J Obes (Lond) 2013;37:382-389.
  43. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, Nakao K: Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 2011;152:2634-2643.
  44. Lasselin J, Laye S, Dexpert S, Aubert A, Gonzalez C, Gin H, Capuron L: Fatigue symptoms relate to systemic inflammation in patients with type 2 diabetes. Brain Behav Immun 2012;26:1211-1219.
  45. Cavelti-Weder C, Furrer R, Keller C, Babians-Brunner A, Solinger AM, Gast H, Fontana A, Donath MY, Penner IK: Inhibition of IL-1β improves fatigue in type 2 diabetes. Diabetes Care 2011;34:e158.
  46. Bower JE, Ganz PA, Aziz N, Fahey JL: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-611.
    External Resources
  47. Raison CL, Lin JM, Reeves WC: Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 2009;23:327-337.
  48. Cho HJ, Seeman TE, Bower JE, Kiefe CI, Irwin MR: Prospective association between C-reactive protein and fatigue in the Coronary Artery Risk Development in Young Adults study. Biol Psychiatry 2009;66:871-878.
  49. Sweat V, Starr V, Bruehl H, Arentoft A, Tirsi A, Javier E, Convit A: C-reactive protein is linked to lower cognitive performance in overweight and obese women. Inflammation 2008;31:198-207.
  50. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
  51. Dinel AL, Andre C, Aubert A, Ferreira G, Laye S, Castanon N: Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One 2011;6:e24325.
  52. Mangge H, Summers KL, Meinitzer A, Zelzer S, Almer G, Prassl R, Schnedl WJ, Reininghaus E, Paulmichl K, Weghuber D, Fuchs D: Obesity-related dysregulation of the tryptophan-kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity (Silver Spring) 2013, E-pub ahead of print, doi: 10.1002/oby.20491.
  53. Pasquali R, Vicennati V, Cacciari M, Pagotto U: The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann NY Acad Sci 2006;1083:111-128.
  54. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR: Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010;68:748-754.
  55. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD: Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407-414.
  56. Carnell S, Gibson C, Benson L, Ochner CN, Geliebter A: Neuroimaging and obesity: current knowledge and future directions. Obes Rev 2012;13:43-56.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: February 14, 2014
Issue release date: February 2014

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 1

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.